# Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

> **NCT06139991** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 66 (actual)

## Conditions studied

- Heathy Participants

## Interventions

- **DRUG:** Treatment A (BDA MDI HFO)
- **DRUG:** Treatment B (BDA MDI HFA)

## Key facts

- **NCT ID:** NCT06139991
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-16
- **Primary completion:** 2024-05-04
- **Final completion:** 2024-05-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06139991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06139991, "Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06139991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*